The active ingredient of red yeast rice (Monascus purpureus), monacolin, has been found in inconsistent amounts in 12 dietary supplements, according to a study conducted by ConsumerLab.com (White Plains, NY).
The active ingredient of red yeast rice (Monascus purpureus), monacolin, has been found in inconsistent amounts in 12 dietary supplements, according to a study conducted by ConsumerLab.com (White Plains, NY).
Monacolin is a naturally-occurring statin that is believed to give red yeast rice its cholesterol-lowering effect. The supplement is often considered by patients with high cholesterol who seek a natural alternative to statin drug therapy.
While each tested product was labeled with 600mg of the active content, according to ConsumerLab, “striking variability” was found in the active amounts of total monacolins, monacolin K, and monacolin KA. The company adds that four of the products even had high amounts of citrinin, a potentially toxic compound.
“We found striking variability in monacolincontent in 12 proprietary RYR products and the presence of citrininin one-third of the formulations tested. Although RYR may havepotential as an alternative lipid-lowering agent, our findingssuggest the need for improved standardization of RYR productsand product labeling.”
The study was published on Monday in the Archives of Internal Medicine.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.